Eli Lilly’s investigational triple-agonist retatrutide outperformed Novo Nordisk’s Ozempic in a large head-to-head Phase 3 trial in adults with type 2 diabetes, with stronger blood sugar and weight outcomes reported at the topline level. The update also noted higher side-effect rates and more discontinuations compared with Ozempic. The results further tighten the competitive race for next-generation metabolic drugs that aim to drive both glycemic control and clinically meaningful weight loss. For developers, the trade-off on tolerability may shape label design, patient selection strategies, and the durability of real-world adherence.